Although patients with node negative breast cancer are thought to have a good prognosis, approximately 25% will have relapsed 5 years after primary treatment (Friedman et al., 1986) . It is clear from extensive clinical experience that relapse is almost always associated with subsequent death from breast cancer. Thus, if approximately one-quarter of patients with node negative breast cancer die of their disease, this is only a good prognosis in relation to node positive disease; it is a poor prognosis in relation to no disease.
Patients with node negative disease who relapse do so on average later than those with node positive disease (NissenMeyer et al., 1986) . This suggests that at presentation they have a smaller tumour burden. Since experimental data indicate that adjuvant chemotherapy is more active the smaller the tumour burden, these patients should theoretically benefit from treatment more than those with node positive disease.
We therefore decided to test the hypothesis that patients with node negative disease would benefit from chemotherapy by using oral chlorambucil, methotrexate and fluorouracil (LMF). Treatment was to begin as soon as possible after mastectomy in view of the Nissen-Meyer study which showed an advantage for early treatment (Nissen-Meyer et al., 1986) .
The trial was started in December 1976 as a multicentre study within the West Midlands region of the United Kingdom. Preliminary analyses of the study were reported when the median follow-up times were 22, 54 and 60 months (Morrison et al., 1981 (Morrison et al., , 1984 (Morrison et al., , 1987 . This paper presents a more complete analysis of the trial 10 years after recruitment began when the median follow-up was 7 years. (Forrest et al., 1976 (Elston et al., 1982) was a modification of the system used by Bloom and Richardson (1957) . Oestrogen and progesterone receptors were assayed using the dextran coated charcoal method and Scatchard analysis (McGuire & De La Garza, 1973 
Patients and methods

Selection ofpatients
Statistical analyses
The major end-points of the trial were histologically or radiologically defined recurrence and death. The completeness of the notification of death was verified by registration of all patients with the West Midlands Regional Cancer Registry, Birmingham, and the National Health Service Central Register, Southport. In accordance with accepted statistical practice, this permitted all randomised patients to be included in the survival analysis (Peto et al., 1977) . However, since there was no notification by clinicians of disease status for patients who were randomised but were found subsequently to be ineligible, only eligible patients are included in the analysis of recurrence, relapse-free survival and toxicity. Relapse-free survival and overall survival curves were drawn using the method of Kaplan and Meier (1958) and the significance of the differences between curves assessed using the log rank test (Peto et al., 1977) . Treatment comparisons were stratified by menopausal status and tumour size. In addition the effect of controlling for menopausal status, tumour size, age, tumour grade and receptor content was determined using Cox's multiple regression analysis (Cox, 1972) . The reduction in the odds of relapse and death (Early Breast Cancer Trialists' Collaborative Group, 1988) and relative improvements were calculated. Patients with uncertain menopausal status (e.g. previous hysterectomy) were taken to be premenopausal if less than 50 years and postmenopausal if 50 years or more. Patients were taken to be post-menopausal if they had had no periods within the previous 6 months.
Results
Patients analysed A total of 574 patients were randomised (285 treated and 289 control) of whom 543 (273 treated and 270 control) were eligible according to the criteria given above. Data were censored at 31 December 1986 when the median follow-up was 7 years. Analysis of survival includes all randomised patients whereas other analyses were performed on eligible patients only; the 31 ineligible patients (13 treated and 18 control) were not followed up. Patients were excluded after randomisation for the following reasons: nodes not sampled or node positive (four treated, five control); advanced disease (two treated); too old (two treated, five control); white blood count too low (one control); abnormal LFTs (two treated, four control); other malignancy (one treated, two control); carcinoma in situ (one treated); benign lump (one control); intercurrent disease (one treated). One treated patient was completely lost to follow-up and is not included in the analysis of recurrence. The characteristics of the eligible patients are given in Table I , which shows that there are no major imbalances of prognostic factors between the treated and control groups.
Relapse-free survival Adjuvant chemotherapy had no significant effect on relapsefree survival (Figure 1 , Table II ). The percentage relapse-free at 5 years is 73% (95% confidence interval (CI) 67-78%) in the treated and 71% (CI 65-76%) in the control group, which represents a relative improvement (RI) of 3% in the relapse rate at 5 years or an 11% reduction in the odds of relapse (OR). After stratification for menopausal status and tumour size, the X2, is 0.51 (P = 0.47). Controlling for menopausal status, tumour size, age, grade and receptor status does not alter the result. For comparability with other Table II . Since there was no effect of chemotherapy overall, further subgroup analyses are not presented. There were 81 (30%) patients who recurred in the treated group and 88 (33%) in the control group. Although the total number of recurrences is similar in both groups, there was a highly significant difference in the distribution of metastases between the treated and control groups (x2, = 8.5; P = 0.0004), 65% having distant recurrence in the treated group and only 43% in the control group (Table III ). An equal number of local recurrences is expected in the treated and control groups, but there were significantly more local recurrences in the control group than expected on the basis of a 1:1 ratio (X2, = 6.5; 0.02> P >0.01). However, although there was a greater number of distant recurrences than expected in the treated group, the deviation from a 1:1 ratio was not significant (X2I = 2.4; 0.2>P >0.1). The severity and duration of nausea and vomiting are outlined in Figure 3 . Severe symptoms were uncommon. However, when symptoms occurred, they lasted for longer than 24 hours in approximately a third of the cycles assessed.
An assessment of the 'quality of life' of patients is shown in Figure 3 . Patients were asked how long they were unwell, how long they were unable to go to work (or perform housework) and how long they were confined to bed if they The results of other trials comparing the use of prolonged combination chemotherapy with a no treatment control arm in node negative patients are shown in Table V (Koyama et al., 1980; Senn et al., 1986; Semiglazov et al., 1986; Jakesz et al., 1987; Ludwig Breast Cancer Study Group, 1989; Espie et al., 1987; Bonadonna et al., 1987; Williams et al., 1987; Mansour et al., 1989; Fisher et al., 1989) . In most, low dose oral or intravenous treatments have been studied in node (Jakesz, 1987) , there have been no reported improvements in survival in this type of study, which is not surprising in view of the small absolute improvement possible in this good prognosis group and the small sample sizes. Several studies report marginal improvements in relapse free survival (Senn et al., 1986; Semiglazov et al., 1986 ; Ludwig Breast Cancer Study Group, 1989) . There is no significant improvement in either relapsefree or overall survival in our trial. This could be due to the chemotherapy used. In the overview of the Early Breast Cancer Trialists' Collaborative Group (1988) CMF-based regimens gave greater reductions in odds than regimens without all or some of C, M, F and single agents, although there was no significant heterogeneity between types of regimen. However, Senn et al. (1986) report significantly improved relapse-free survival with LMF and our failure to demonstrate any significant benefit could be due to chance and the relatively small number of patients studied for the magnitude of improvement that now seems likely in this group. These trials in unselected node negative patients are confounded not only by the relatively small numbers of patients but also by the relatively low number and late occurrence of events in node negative patients. More recent trials have tried to select high risk groups on the basis of oestrogen receptor status. These studies have all demonstrated highly significant improvements in relapse free survival. In the NSAPB study (Fisher et al., 1989) , 741 node negative, ER negative patients
